Forest's Flumadine
Executive Summary
St. Louis-based Buck Pharmacal will co-promote the Haemophilus A influenzae treatment. Buck will contribute 240 sales people to Forest's current sales force of 400 for Flumadine (rimantadine HCl). The combined marketing group will continue to promote Flumadine to primary care and pediatric physicians. Forest says more than 500,000 scripts were written for Flumadine during the 1993-94 flu season in an estimated market of 25-75 mil. people annually who contract the flu. Forest began marketing the drug in September 1993 ("The Pink Sheet" Sept. 20, 1993, T&G-1)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth